Insight

Yüksel Ürün: A study from Sweden on over 350,000 men

Photo from Yüksel Ürün/X

May 14, 2024, 13:15

Yüksel Ürün: A study from Sweden on over 350,000 men

Yüksel Ürün shared on X:

“A study from Sweden on over 350,000 men: .

α1-adrenoceptor antagonists do not increase mortality from prostate cancer nor the risk of high-grade prostate cancer.
However, these drugs are linked to a slight increase in overall prostate cancer incidence, especially lower-grade types. Possible detection bias?
These medications include alfuzosin, doxazosin, terazosin, tamsulosin, and prazosin. These medications are FDA-approved to treat benign prostatic hyperplasia (BPH).“

Source: Yüksel Ürün/X

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes.

His dedication to patient care and research inspires positive change in the medical field.

alfuzosin Ankara University School of Medicine benign prostatic hyperplasia (BPH). cancer doxazosin OncoDaily Oncology prazosin prostate cancer Sweden tamsulosin terazosin Yüksel Ürün α1-adrenoceptor antagonists

Rod Stewart and Prostate Cancer: How He Went Against, How He Survived, and More

Celebrating the Holiday Magic with Medical Community

Melanie Griffith and Skin Cancer: How She Went Against, How She Survived, and More

2024 ASCO Election Results

New Paper Alert! HR+ Breast Cancer: Efficacy of Subsequent Treatments After CDK4/6 Inhibitor Progression

Special Coverage